Immunocore announces dosing of first patient with third ImmTAC® bispecific

Immunocore Limited, a leading T Cell Receptor (TCR) biotechnology company, today announced the start of the first-in-human clinical trial of IMC-C103C, the third bispecific developed using the companys innovative ImmTAC technology platform.